These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1342 related items for PubMed ID: 25455500

  • 1. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H, Siddig S, Uzu M, Suzuki S, Nomura Y, Kashiba T, Gushimiyagi K, Sekine Y, Uehara T, Arano Y, Yamaura K, Ueno K.
    Eur J Pharmacol; 2015 Jan 05; 746():258-66. PubMed ID: 25455500
    [Abstract] [Full Text] [Related]

  • 2. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.
    Cancer Lett; 2009 Jun 28; 279(1):74-83. PubMed ID: 19232821
    [Abstract] [Full Text] [Related]

  • 3. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
    Shukla S, Robey RW, Bates SE, Ambudkar SV.
    Drug Metab Dispos; 2009 Feb 28; 37(2):359-65. PubMed ID: 18971320
    [Abstract] [Full Text] [Related]

  • 4. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK, Poon DC, Wei Y, Wang F, Lin G, Fu LW.
    Biochem Pharmacol; 2015 Sep 01; 97(1):27-37. PubMed ID: 26206183
    [Abstract] [Full Text] [Related]

  • 5. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
    Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, Schinkel AH.
    J Pharmacol Exp Ther; 2012 Apr 01; 341(1):164-73. PubMed ID: 22238213
    [Abstract] [Full Text] [Related]

  • 6. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2012 Jan 01; 130(1):223-33. PubMed ID: 21351087
    [Abstract] [Full Text] [Related]

  • 7. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2014 Mar 15; 134(6):1484-94. PubMed ID: 24037730
    [Abstract] [Full Text] [Related]

  • 8. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
    Teng YN, Sheu MJ, Hsieh YW, Wang RY, Chiang YC, Hung CC.
    Phytomedicine; 2016 Mar 15; 23(3):316-23. PubMed ID: 26969385
    [Abstract] [Full Text] [Related]

  • 9. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J, Zhang X, Wang F, Wang X, Yang K, Xu M, To KK, Li Q, Fu L.
    Oncotarget; 2015 Dec 29; 6(42):44643-59. PubMed ID: 26556876
    [Abstract] [Full Text] [Related]

  • 10. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
    Darby RA, Unsworth A, Knapp S, Kerr ID, Callaghan R.
    Cancer Chemother Pharmacol; 2015 Oct 29; 76(4):853-64. PubMed ID: 26351135
    [Abstract] [Full Text] [Related]

  • 11. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE, Ifergan I, Grimberg M, Lemke K, Skladanowski A, Assaraf YG.
    Biochem Pharmacol; 2007 Jun 30; 74(1):41-53. PubMed ID: 17481587
    [Abstract] [Full Text] [Related]

  • 12. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Mol Pharm; 2012 Nov 05; 9(11):3236-45. PubMed ID: 23020847
    [Abstract] [Full Text] [Related]

  • 13. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH.
    Cancer Res; 2005 Apr 01; 65(7):2577-82. PubMed ID: 15805252
    [Abstract] [Full Text] [Related]

  • 14. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV.
    Mol Cell Biochem; 2007 Feb 01; 296(1-2):85-95. PubMed ID: 16960658
    [Abstract] [Full Text] [Related]

  • 15. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW.
    Cancer Res; 2008 Oct 01; 68(19):7905-14. PubMed ID: 18829547
    [Abstract] [Full Text] [Related]

  • 16. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
    To KKW, Wu X, Yin C, Chai S, Yao S, Kadioglu O, Efferth T, Ye Y, Lin G.
    J Ethnopharmacol; 2017 May 05; 203():110-119. PubMed ID: 28363522
    [Abstract] [Full Text] [Related]

  • 17. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Zhang H, Wang YJ, Zhang YK, Wang DS, Kathawala RJ, Patel A, Talele TT, Chen ZS, Fu LW.
    Cancer Lett; 2014 Aug 01; 350(1-2):61-8. PubMed ID: 24747122
    [Abstract] [Full Text] [Related]

  • 18. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
    Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, Staud F.
    Clin Exp Pharmacol Physiol; 2006 Aug 01; 33(1-2):58-65. PubMed ID: 16445700
    [Abstract] [Full Text] [Related]

  • 19. ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells.
    Mirzaei SA, Gholamian Dehkordi N, Ghamghami M, Amiri AH, Dalir Abdolahinia E, Elahian F.
    Toxicol Appl Pharmacol; 2017 Dec 15; 337():22-29. PubMed ID: 29079042
    [Abstract] [Full Text] [Related]

  • 20. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
    Fleisher B, Unum J, Shao J, An G.
    J Pharm Sci; 2015 Jan 15; 104(1):266-75. PubMed ID: 25418056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.